- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04259736
Prospective Cohort Study of Molecular Mechanism of Lower Respiratory Tract Microbes in Patients With AECOPD (REASON)
A Prospective Cohort Study of Molecular Mechanism of Lower Respiratory Tract Microbes in Patients With Acute Obstructive Pulmonary Disease (AECOPD) by Regulating the Transcriptional Balance of NF-κB and PPARγ in Alveolar Macrophages
Study Overview
Status
Detailed Description
This study will be based on a prospective cohort design in patients with COPD who are eligible for the study. Fifty patients who met the criteria for inclusion and exclusion of COPD exacerbations and signed informed consent will participate in the study. The purpose of this study is to evaluate the effect of the lower respiratory tract microbiome on lung tissue remodeling, decreased lung function, and clinical symptoms in patients with AECOPD.
Baseline screening includes demographic data, medical history, combined medication records, symptoms, signs, symptom scores, number of acute exacerbations, blood cells and inflammatory factors, electrocardiogram, lung function, alveolar lavage fluid microbe NGS, and safety observation indicators.
Patients will be followed up every 3 months for a period of 1 year. The primary and secondary endpoints are as follows.
Primary endpoint: Changes in FEV1 (forced expiratory volume in the first second) within 1 year of follow-up
Secondary endpoint: Changes in CAT, CCQ, mMRC scores during 1 year of follow-up Changes in lung function during 1 year of follow-up: FEV1 / FVC Changes in blood routine, IgE, and eosinophil count within 1 year of follow-up Number of hospital admissions due to acute exacerbation during 1 year of follow-up
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Shengqing Li, PhD
- Phone Number: +8602152887072
- Email: shengqingli9655@163.com
Study Contact Backup
- Name: Jingwen Xia, MD
- Phone Number: +8602152887072
- Email: xjw2006@126.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Recruiting
- Huashan Hospital,Fudan University
-
Contact:
- Shengqing Li, PhD
- Phone Number: 02152887072
- Email: shengqingli9655@163.com
-
Contact:
- Jingwen Xia, MD
- Phone Number: +8602152887072
- Email: xjw2006@126.com
-
Sub-Investigator:
- Jingwen Xia, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with a diagnosis of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) according to the GOLD2018 guidelines (patients with FEV1pred> 30% and no concurrent respiratory failure);
- Age ≥18, ≤80 years, regardless of gender;
- No antibiotics have been used after this acute exacerbation;
- Treatment according to GOLD guidelines;
Those with the following bronchoscopy indications:
- Collect lower respiratory tract secretions for bacteriological examination;
- Chest radiographs have invasive lesions of unknown origin;
- bronchoalveolar lavage, bronchial administration and suction treatment;
- unexplained hemoptysis or chronic irritating cough;
- Bronchial obstructions such as localized wheezing, localized emphysema, obstructive pneumonia, or any atelectasis;
- Suspected of trachea and bronchial tumors;
- paralysis of the recurrent laryngeal or phrenic nerve of unknown cause;
- Cancer cells or Mycobacterium tuberculosis are found in sputum and no lesions are found on chest radiograph;
- Suspected of bronchial foreign bodies or stones;
- diffuse lesions of the lungs or masses around the lungs that require lung biopsy, brushing, or lavage for cytology or bacteriological examination to confirm the diagnosis;
- Patients who have a long-term indwelling cannula after tracheotomy and know whether the trachea is damaged or necrotic;
- hilar swollen, unexplained lung mass;
- Select lipiodol or iodine radiography of a lung lobe or segment.
- Voluntary signed informed consent.
Exclusion Criteria:
- active phase of tuberculosis;
- Patients with malignant tumor disease;
- patients with rheumatic diseases;
- Patients with contraindications to bronchoscopy;
- patients with mental illness;
- Exclude those with severe medical diseases: such as heart, liver, and kidney dysfunction or coagulation dysfunction; uncontrolled hypertension, hyperglycemia or arrhythmia;
- pregnancy and lactation;
- Patients who participated in other clinical trials in the past 3 months;
- Staff members and their families in this research institution.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FEV1
Time Frame: 12 months
|
Forced expiratory volume in the first second
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CAT scores
Time Frame: 12 months
|
COPD Assessment Test score; Score: 0-10, Low impact; Score: 10-20, Moderate impact; Score 20-30, High impact; Score 30-40, Very high impact.
|
12 months
|
mMRC scores
Time Frame: 12 months
|
The modified British Medical ResearchCouncil (mMRC) questionnaire total score ranges from 0 to 4, with higher grades indicating more severe breathlessness.
|
12 months
|
other lung function parameters
Time Frame: 12 months
|
FEV1/ FVC
|
12 months
|
Incidence of COPD exacerbation
Time Frame: 12 months
|
Number of Incidence of COPD exacerbation
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shengqing Li, PhD, Huashan Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY2018-362
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microbiome
-
University Hospital, AntwerpRecruitingSkin Microbiome | Vaginal Microbiome | Saliva MicrobiomeBelgium
-
ProgenaBiomeRecruitingGastrointestinal Microbiome | Gut MicrobiomeUnited States
-
University of California, DavisCompletedGut Microbiome | Skin Microbiome | Gut Lipidome | Skin Lipidome | Blood LipidomeUnited States
-
University of California, Los AngelesCompleted
-
Seraphic Group IncUnknownMicrobiomeUnited States
-
University of California, DavisCompleted
-
Johnson & Johnson Consumer Inc. (J&JCI)Completed
-
University of AarhusAarhus University Hospital; University of Copenhagen; Arla FoodsActive, not recruitingBreast Milk Collection | Infant Gut Microbiome | Human Milk/Breastfeeding | Human Milk MicrobiomeDenmark
-
University Medical Center GroningenCompleted
-
The Gut Microbiome Center (Centar za crijevni mikrobiom)University of ZagrebCompletedGastrointestinal MicrobiomeCroatia